Doximity, Inc. (DOCS) P/E Ratio History
Fairly ValuedTrading at 43.7x, near 5Y avg of 49.7x · 40th percentile · In line with own history · Data 2022–2027
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Doximity, Inc. (DOCS) trades at a price-to-earnings ratio of 43.7x, with a stock price of $32.51 and trailing twelve-month earnings per share of $0.74.
The current P/E is 12% below its 5-year average of 49.7x. Over the past five years, DOCS's P/E has ranged from a low of 23.5x to a high of 91.6x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, DOCS trades at a 78% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
The PEG ratio of 0.84 (P/E divided by -12% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, DOCS commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DOCS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DOCS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
DOCS P/E vs Peers
Life Sciences Software peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $177B | 126.5 | - | -11% | |
| $49B | 49.4 | 2.72 | +26% | |
| $1B | 7.1Lowest | 0.69Best | +817%Best | |
| $3B | 31.1 | 4.64 | +14% | |
| $31B | 25.7 | - | +132% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
DOCS Historical P/E Data (2022–2027)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2027 Q2 | Sep 30 2026 | $28.34 | $0.72 | 39.4x | -47% |
| FY2027 Q1 | - | $20.74 | $0.85 | 24.4x | -67% |
| FY2026 Q4 | - | $23.30 | $0.99 | 23.5x | -69% |
| FY2026 Q3 | Dec 31 2025 | $44.28 | $1.20 | 36.9x | -51% |
| FY2026 Q2 | - | $73.15 | $1.26 | 58.1x | -22% |
| FY2026 Q1 | Jun 30 2025 | $61.34 | $1.17 | 52.4x | -30% |
| FY2025 Q4 | Mar 31 2025 | $58.03 | $1.11 | 52.3x | -30% |
| FY2025 Q3 | - | $53.39 | $1.00 | 53.4x | -29% |
| FY2025 Q2 | Sep 30 2024 | $43.57 | $0.87 | 50.1x | -33% |
| FY2025 Q1 | Jun 30 2024 | $27.97 | $0.80 | 35.0x | -53% |
| FY2024 Q4 | Mar 31 2024 | $26.91 | $0.72 | 37.4x | -50% |
| FY2024 Q3 | Dec 31 2023 | $28.04 | $0.66 | 42.5x | -43% |
| FY2024 Q2 | Sep 30 2023 | $21.22 | $0.58 | 36.6x | -51% |
| FY2024 Q1 | Jun 30 2023 | $34.02 | $0.55 | 61.9x | -17% |
| FY2023 Q4 | Mar 31 2023 | $32.38 | $0.52 | 62.3x | -17% |
| FY2023 Q3 | Dec 31 2022 | $33.56 | $0.55 | 61.0x | -18% |
| FY2023 Q2 | Sep 30 2022 | $30.22 | $0.65 | 46.5x | -38% |
| FY2023 Q1 | - | $34.82 | $0.70 | 49.7x | -34% |
| FY2022 Q4 | - | $52.09 | $0.66 | 79.2x | +6% |
| FY2022 Q3 | Dec 31 2021 | $50.13 | $0.55 | 91.6x | +22% |
| FY2022 Q2 | - | $80.70 | $0.32 | 255.1x | +241% |
| FY2022 Q1 | Jun 30 2021 | $58.20 | $0.15 | 397.8x | +431% |
Average P/E for displayed period: 74.9x
DOCS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DOCS — Frequently Asked Questions
Quick answers to the most common questions about buying DOCS stock.
What is DOCS's P/E ratio?
Doximity, Inc. (DOCS) trailing twelve-month P/E ratio is 43.7x, based on TTM diluted EPS of $0.74. The 5-year average P/E is 49.7x and the historical range spans 23.5x to 91.6x.
Is DOCS stock overvalued or undervalued?
DOCS trades at 43.7x P/E, near its 5-year average of 49.7x. The 40th percentile ranking within the 23.5x–91.6x historical range places valuation within normal bounds.
Is DOCS stock expensive?
DOCS is fairly valued relative to its own history. The current P/E of 43.7x is near the 5-year average of 49.7x (40th percentile of historical range).
What is DOCS's historical P/E range?
Over the past 5 years, DOCS's P/E ratio has ranged from 23.5x to 91.6x, with a median of 50.1x and an average of 49.7x. The current P/E of 43.7x places the stock at the 40th percentile of this range. Full historical data spans 2022–2027.
How does DOCS's P/E compare to the S&P 500?
DOCS trades at 43.7x P/E versus the S&P 500 median of 21.8x. The 100% premium to the market typically reflects higher expected earnings growth or quality.
How does DOCS's valuation compare to Healthcare peers?
Doximity, Inc. P/E of 43.7x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is DOCS's PEG ratio?
DOCS PEG ratio is 0.84, based on a P/E of 43.7x and EPS growth of -11.7%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is DOCS's earnings yield?
DOCS earnings yield is 2.29%, the inverse of its 43.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.